Technology | Heart Valve Technology | August 15, 2017

FDA Clears Aortic Annuloplasty Device for Bicuspid Aortic Valve Repair

The FDA cleared the HAART 200 Aortic Annuloplasty Device for bicuspid aortic valve repair. The devioce is made by BioStable Science and Engineering Inc.

Aug. 15, 2017 — The U.S, Food and Drug Administration (FDA) granted market clearance for the HAART 200 Aortic Annuloplasty Device, the first annuloplasty device designed specifically for bicuspid aortic valve repair. With FDA clearance of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable Science and Engineering Inc. is now able to offer U.S. surgeons a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency. 

A Bicuspid aortic valve (BAV) is a congenital malformation where the aortic valve forms with only two functional valve leaflets instead of the normal three. BAV is the most common congenital heart defect, affecting up to 2 percent of the population, and carries significant risk of cardiovascular complications. Patients with BAV have significantly higher risk of developing aneurysms or dissections of the aorta and approximately 53 percent of patients will require aortic valve replacement within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of re-operation or complications associated with valve replacement technologies. Aortic valve repair is an emerging surgical alternative for patients with bicuspid aortic valve insufficiency that may offer improved patient outcomes compared to valve replacement.[2]

The HAART 200 Aortic Annuloplasty Device is designed to facilitate valve repair in patients with aortic valve insufficiency due to BAV. The device is designed to reduce annular diameter based upon leaflet size, to conform the annulus to a circular, symmetric shape for improved valve function, and to stabilize the annular geometry long-term.

“Surgical repair of the bicuspid aortic valve can be a complex three dimensional problem because of variability in the valve anatomy,” explained Scott Rankin, M.D.,  professor of surgery at West Virginia University Heart and Vascular Institute, and inventor of the HAART device. “Implantation of the HAART 200 Aortic Annuloplasty Device conforms the native valve to the three dimensional shape of the device, creating a circular valve geometry and aligning the leaflet commissures into the preferred 180 degree orientation. Conforming the native valve to this shape simplifies assessment and reconstruction of the valve leaflets and creates a central flow pattern of blood through the valve which may improve the long-term durability of the repair.”

The HAART 200 Aortic Annuloplasty Device is not available for sale outside of the United States.

For more information: www.biostable-s-e.com

Read the article "HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use."

Read the related article "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."
 

References: 

1. Michelena HI1, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011 Sep 14;306(10):1104-12.

2. Vallabhajosyula P, Szeto WY, Habertheuer A. et al. Bicuspid aortic insufficiency with aortic root aneurysm: root reimplantation versus Bentall root replacement. Ann Thoracic Surg 2016;102:1221-8.

 

Related Content

Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings | October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init